JP7783802B2 - 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 - Google Patents

疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Info

Publication number
JP7783802B2
JP7783802B2 JP2022503935A JP2022503935A JP7783802B2 JP 7783802 B2 JP7783802 B2 JP 7783802B2 JP 2022503935 A JP2022503935 A JP 2022503935A JP 2022503935 A JP2022503935 A JP 2022503935A JP 7783802 B2 JP7783802 B2 JP 7783802B2
Authority
JP
Japan
Prior art keywords
composition
compound
alkyl
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022503935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542238A (ja
JP2022542238A5 (enExample
Inventor
カルメン オニシウ，ダニエラ
Original Assignee
エスパーヴィタ セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスパーヴィタ セラピューティクス，インコーポレイテッド filed Critical エスパーヴィタ セラピューティクス，インコーポレイテッド
Publication of JP2022542238A publication Critical patent/JP2022542238A/ja
Publication of JP2022542238A5 publication Critical patent/JP2022542238A5/ja
Priority to JP2025207487A priority Critical patent/JP2026048714A/ja
Application granted granted Critical
Publication of JP7783802B2 publication Critical patent/JP7783802B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/34—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings containing more than one carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022503935A 2019-07-26 2020-07-23 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 Active JP7783802B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025207487A JP2026048714A (ja) 2019-07-26 2025-11-28 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962878852P 2019-07-26 2019-07-26
US62/878,852 2019-07-26
US201962901739P 2019-09-17 2019-09-17
US62/901,739 2019-09-17
PCT/US2020/043274 WO2021021563A1 (en) 2019-07-26 2020-07-23 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025207487A Division JP2026048714A (ja) 2019-07-26 2025-11-28 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Publications (3)

Publication Number Publication Date
JP2022542238A JP2022542238A (ja) 2022-09-30
JP2022542238A5 JP2022542238A5 (enExample) 2023-08-16
JP7783802B2 true JP7783802B2 (ja) 2025-12-10

Family

ID=74189909

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022503935A Active JP7783802B2 (ja) 2019-07-26 2020-07-23 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸
JP2025207487A Pending JP2026048714A (ja) 2019-07-26 2025-11-28 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025207487A Pending JP2026048714A (ja) 2019-07-26 2025-11-28 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Country Status (14)

Country Link
US (8) US11098002B2 (enExample)
EP (2) EP4003314B1 (enExample)
JP (2) JP7783802B2 (enExample)
KR (1) KR20220039754A (enExample)
CN (2) CN118903087A (enExample)
AU (2) AU2020321945B2 (enExample)
BR (1) BR112022000993A2 (enExample)
CA (1) CA3143294C (enExample)
ES (1) ES2991100T3 (enExample)
IL (1) IL289919B2 (enExample)
MX (2) MX2022000570A (enExample)
TW (2) TW202532387A (enExample)
WO (1) WO2021021563A1 (enExample)
ZA (1) ZA202110502B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098002B2 (en) 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
HUE071473T2 (hu) * 2020-04-15 2025-09-28 Medivir Ab MIV-818/lenvatinib kombinációs terápia májrák kezelésére
WO2022159811A1 (en) * 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
CA3209453A1 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease
CA3203644A1 (en) * 2021-02-26 2022-09-01 Obi Pharma, Inc. Use of akr1c3-activated compound
KR20240004519A (ko) * 2021-04-28 2024-01-11 아센타위츠 파마슈티컬즈 리미티드 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법
CN115887435A (zh) * 2021-09-23 2023-04-04 博骥源（上海）生物医药有限公司 长链类化合物及其用途
CN114736191B (zh) * 2022-04-01 2023-08-08 上海工程技术大学 特普替尼中间体及其制备方法和应用
CN114949230B (zh) * 2022-06-13 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN115844887B (zh) * 2022-12-28 2023-09-08 中国人民解放军空军军医大学 Selonsertib在制备治疗癌症的药物中的用途
KR102928747B1 (ko) 2023-07-21 2026-02-26 대한민국 피라졸로[1,5-에이]퀴나졸린 유도체 화합물을 포함하는 인간면역결핍바이러스 억제용 조성물
CN117843938B (zh) * 2024-03-08 2024-05-24 华东理工大学 一种类聚烯烃的长碳链聚酯弹性体、制备方法及其应用
CN120131672B (zh) * 2025-04-28 2025-12-26 山东大学 乐伐替尼联合熊去氧胆酸在肝癌治疗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387672A (en) 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US20030236212A1 (en) 2002-04-10 2003-12-25 Jean-Louis Dasseux Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses
US20040171688A1 (en) 1997-06-26 2004-09-02 Jacob Bar-Tana Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US397037A (en) 1889-01-29 Conductor-support
US2789970A (en) 1953-12-08 1957-04-23 Eastman Kodak Co Polycarbonates from 1, 4-bis-(beta-hydroxyethyl)-benzenes-bis
GB900875A (en) 1959-11-12 1962-07-11 Sierra Eng Co Check valve
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2410782C2 (de) 1974-03-07 1982-02-18 Dynamit Nobel Ag, 5210 Troisdorf Phenylendiessigsäuredialkylester und Verfahren zu deren Herstellung
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6410802B1 (en) 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
CA2425311C (en) 2000-10-11 2011-06-14 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
ES2625429T3 (es) 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
US7638531B2 (en) 2005-12-21 2009-12-29 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
SG189019A1 (en) 2010-10-18 2013-05-31 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
CN105997967B (zh) 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
US20140378922A1 (en) 2013-06-25 2014-12-25 Basf Se Fluid-absorbent article with indicator
WO2016077832A2 (en) 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
AU2016253972B2 (en) 2015-04-27 2020-01-02 Acuitas Therapeutics Inc. Nucleoside-modified RNA for inducing an adaptive immune response
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CN105801405A (zh) 2016-05-23 2016-07-27 天津迪尔斯化学科技有限公司 一种降血脂小分子化合物、中间体及各自制备方法
US10004761B2 (en) 2016-06-21 2018-06-26 Mark M. Levy Malodor neutralizing composition
CN110200981A (zh) 2019-06-06 2019-09-06 中国药科大学 五环三萜皂苷的医药用途及其药物组合物
US11098002B2 (en) 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
WO2022159811A1 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
CA3209453A1 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387672A (en) 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US20040171688A1 (en) 1997-06-26 2004-09-02 Jacob Bar-Tana Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US20030236212A1 (en) 2002-04-10 2003-12-25 Jean-Louis Dasseux Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses

Also Published As

Publication number Publication date
EP4003314C0 (en) 2024-07-10
US20210269384A1 (en) 2021-09-02
IL289919B2 (en) 2025-10-01
TW202532387A (zh) 2025-08-16
ZA202110502B (en) 2025-04-30
US20210024447A1 (en) 2021-01-28
BR112022000993A2 (pt) 2022-06-07
MX2022000570A (es) 2022-03-11
TW202118750A (zh) 2021-05-16
US12180151B2 (en) 2024-12-31
WO2021021563A1 (en) 2021-02-04
EP4003314A1 (en) 2022-06-01
AU2025201689A1 (en) 2025-03-27
EP4464688A1 (en) 2024-11-20
IL289919B1 (en) 2025-06-01
JP2022542238A (ja) 2022-09-30
US20240417363A1 (en) 2024-12-19
US11084773B1 (en) 2021-08-10
US11267778B2 (en) 2022-03-08
AU2020321945B2 (en) 2025-02-13
EP4003314A4 (en) 2023-09-20
US20230007838A1 (en) 2023-01-12
TWI862642B (zh) 2024-11-21
MX2025002978A (es) 2025-04-02
US11098002B2 (en) 2021-08-24
US20240092721A1 (en) 2024-03-21
US20250367149A1 (en) 2025-12-04
US20210221765A1 (en) 2021-07-22
AU2020321945A1 (en) 2022-01-20
IL289919A (en) 2022-03-01
EP4003314B1 (en) 2024-07-10
CN114126593B (zh) 2024-07-26
CN114126593A (zh) 2022-03-01
JP2026048714A (ja) 2026-03-17
US12252467B2 (en) 2025-03-18
KR20220039754A (ko) 2022-03-29
ES2991100T3 (es) 2024-12-02
CN118903087A (zh) 2024-11-08
CA3143294A1 (en) 2021-02-04
CA3143294C (en) 2024-06-11
US20220402851A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
JP7783802B2 (ja) 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸
CA2500977A1 (en) 2-thiohydantoine derivative compounds and use thereof in therapeutics
JP2024122966A (ja) 芳香族化合物およびその医薬用途
KR20230152007A (ko) 작용화된 장쇄 카복실산, 및 질환의 치료를 위한 이의 용도
RU2839725C2 (ru) Функционализированные моно- и дикарбоновые кислоты с длинной углеводородной цепью и их применение для предотвращения или лечения заболеваний
TW202245804A (zh) 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
HK40065893A (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
HK40065893B (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
HK40063169A (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
JP5291721B2 (ja) 置換３−ヒドロキシピリジン及びその医薬組成物
HK40063169B (zh) 可用於预防或治疗疾病的官能化的长链烃一元和二元羧酸
BR122024018347A2 (pt) Compostos, seus usos na prevenção ou tratamento de doenças, e composição farmacêutica
CN118119386A (zh) 官能化羧酸以及其用于治疗疾病的用途
CZ20021786A3 (cs) Deriváty 2-arylchinolinu, způsob jejich přípravy a farmaceutické kompozice, které je obsahují
JPH04316568A (ja) 共役γ−ヒドロキシブテノライド化合物およびこれを有効成分とする制ガン剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251128

R150 Certificate of patent or registration of utility model

Ref document number: 7783802

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150